PMID- 36313305
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221102
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 13
DP  - 2022
TI  - Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: A 
      bayesian network meta-analysis.
PG  - 998816
LID - 10.3389/fphar.2022.998816 [doi]
LID - 998816
AB  - Background: In light of clinical trials comparing different doses of tirzepatide 
      with selective glucagon-like peptide-1 receptor agonist (GLP1-RA) or insulin 
      analogue, a bayesian network meta-analysis was conducted to investigate the 
      efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus 
      (T2DM). Methods: We systematically searched PubMed, Embase, Web of science, 
      Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov from their 
      inception to 2 May 2022. Final included studies met the eligibility criteria and 
      methodological quality recommendations. Data analysis was performed using Stata 
      15.1 software. Each outcome was presented as a mean difference or an odds ratio, 
      and the surface under the cumulative ranking curve value (SCURA). Results: 
      Ultimately, eight eligible RCTs involving 7245 patients were included. Generally 
      speaking, compared with basal insulin (glargine or degludec); selective GLP1-RA 
      (dulaglutide or semaglutide once weekly), 10 and 15 mg of tirzepatide exhibited 
      better antidiabetic and weight-loss effect, especially, 15 mg of tirzepatide was 
      dominant on reducing glycated hemoglobin (SCURA probability: 93.5%), body weight 
      (99.7%), and fasting serum glucose (86.6%). As for safety, insulin caused less 
      gastrointestinal events (93.5%), and there was no statistical difference between 
      GLP1-RA and tirzepatide. Conclusion: Compare with insulin and GLP1-RA, 
      tirzepatide display favorable efficacy and acceptable safety for T2DM patients. 
      More well-designed RCTs are needed to evaluate its clinical performance with 
      higher doses of GLP1-RA and determine its potential cardiovascular benefits.
CI  - Copyright (c) 2022 Guan, Yang, Yang, Du, Li and Ma.
FAU - Guan, Ruifang
AU  - Guan R
AD  - Department of Clinical Pharmacy, School of Pharmacy, Fudan University, Shanghai, 
      China.
AD  - Department of Clinical Pharmacology, Zhongshan Hospital, Fudan University, 
      Shanghai, China.
FAU - Yang, Qing
AU  - Yang Q
AD  - Department of Clinical Pharmacy, School of Pharmacy, Fudan University, Shanghai, 
      China.
FAU - Yang, Xiaolei
AU  - Yang X
AD  - Department of Clinical Pharmacy, School of Pharmacy, Fudan University, Shanghai, 
      China.
FAU - Du, Wandi
AU  - Du W
AD  - Department of Clinical Pharmacy, School of Pharmacy, Fudan University, Shanghai, 
      China.
FAU - Li, Xuening
AU  - Li X
AD  - Department of Clinical Pharmacology, Zhongshan Hospital, Fudan University, 
      Shanghai, China.
FAU - Ma, Guo
AU  - Ma G
AD  - Department of Clinical Pharmacy, School of Pharmacy, Fudan University, Shanghai, 
      China.
LA  - eng
PT  - Systematic Review
DEP - 20221014
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC9613929
OTO - NOTNLM
OT  - efficacy
OT  - network meta-analysis
OT  - safety
OT  - tirzepatide
OT  - type 2 diabetes mellitus
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/11/01 06:00
MHDA- 2022/11/01 06:01
PMCR- 2022/10/14
CRDT- 2022/10/31 04:55
PHST- 2022/07/20 00:00 [received]
PHST- 2022/09/28 00:00 [accepted]
PHST- 2022/10/31 04:55 [entrez]
PHST- 2022/11/01 06:00 [pubmed]
PHST- 2022/11/01 06:01 [medline]
PHST- 2022/10/14 00:00 [pmc-release]
AID - 998816 [pii]
AID - 10.3389/fphar.2022.998816 [doi]
PST - epublish
SO  - Front Pharmacol. 2022 Oct 14;13:998816. doi: 10.3389/fphar.2022.998816. 
      eCollection 2022.